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Nature Outlooks are sponsored supplements that aim to stimulate interest and debate around a subject of interest to the sponsor, while satisfying the editorial values of Nature and our readers' expectations. The boundaries of sponsor involvement are clearly delineated in the Nature Outlook editorial guidelines available at www.nature.com/ advertising/resources/pdf/outlook_guidelines.pdf.
CITING THE OUTLOOK
Cite as a supplement to Nature, for example, Nature Vol XXX, No. XXXX suppl., Sxx-Sxx (2010).
VISIT THE OUTLOOK ONLINE
The Nature Outlook Parkinson's Disease supplement can be found at www.nature.com/nature/outlook/parkinsons/. It features all newly commissioned content as well as a selection of relevant previously published material. All featured articles will be freely available for 3 months. Unlike other neurodegenerative conditions, Parkinson's disease has had a successful symptomatic drug available for more than 40 years. Levodopa is the mainstay of Parkinson's disease treatment, but although its pharmacology and delivery have been altered and improved over the years, it is still far from ideal. And herein lies perhaps the ultimate frustration: despite several decades of searching, levodopa is still the best there is.
SUBSCRIPTIONS AND CUSTOMER SERVICES
That is not the only challenge. Can we detect the disease before major, perhaps irreversible degeneration has occurred? What will it take to replicate this disease in animal models to enhance our understanding of it and aid development of novel treatments? And how can new, potentially disease-modifying therapies be appropriately tested in patients?
As this Nature Outlook reveals, we might be on the brink of a revolution in the diagnosis and treatment of Parkinson's disease. The frustration of failing to find a simple or single cause is giving way to the hope that the complex web of gene and protein interactions might be starting to untangle. Candidate biomarkers for earlier diagnosis are emerging, and many new and exciting treatments are working their way into the clinic.
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